Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 53.92% is 16% below its 1-year average of 63.89%, near the low end of its 1-year range (53.92%–78.37%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.53% below its 12-month average of 60.27%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 53.92%.
DEBT TO ASSETS RATIO
53.92%
DEBT TO ASSETS RATIO AVG TTM
60.27%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-10.53%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+59814.93%
vs the sector median at left
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.03B
Debt to Assets Ratio
53.92%
TTM Avg
60.27%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04B
Debt to Assets Ratio
0.57%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.69M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$996.65M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.03B | 53.92% | 60.27% | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 0.02% | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | 0.57% | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | 0.07% | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.38% | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.03% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.01% | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 0.16% | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.01% | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.01% | N/A | N/A | N/A |
Debt/Assets
53.9%
Debt/Equity
1.59
Current Ratio
1.44
Interest Coverage
0.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 53.92% |
| 2026-03-31 | 54.86% |
| 2025-12-31 | 54.55% |
| 2025-09-30 | 77.76% |
| 2024-12-31 | 78.37% |
